Trinity Biotech (NASDAQ:TRIB) Stock, Quote.Headers.trade-ideas

Trinity Biotech

Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.

Biotech

Earnings

Earnings Beats

Large Cap

Mid Cap

News

Penny Stocks

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

ISRG

TMDX

TRIB

Trinity Biotech plc (NASDAQ: TRIB) recently provided an update on its continued development of its glucose biosensor technology. Earlier this year, the company was granted a European patent for a novel method that enhances the performance of its glucose biosensor.

Will Trinity Biotech Stock Gain From Its Latest Patent Process?

Guidance

Health Care

Movers

Trinity Biotech stock surges on high volume after announcing increased orders for TrinScreen HIV, boosting 2024 revenue projections to $10 million. Second-quarter earnings show a 14% YoY revenue increase driven by strong HIV test sales.

Why Is Clinical Diagnostics Focused Trinity Biotech Stock Trading Higher On Tuesday?

movers image

Pre-Market Outlook

ADXN

ATXG

BLDP

CNET

CTNT

GLPG

GSX Techedu Inc. American Depositary Shares

GOTU

ILAG

MAPS

SMFL

SOPA

TANH

TCOM

TUYA

VVPR

Why Trip.com Group Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket

Trinity Biotech plc - American Depositary Shares

Trinity Biotech PLC

Tribe - United States Dollar

XINDA INTL CORP by Xinda International Corp.

Tribal Rides International Corp

Tribe Capital Growth Corp II

TRIBE PPTY TECHNOLOGIES by Tribe Property Technologies Inc.

Tribe Property Technologies Inc

Tribeca Resources Corp

Trinity Biotech plc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trib#NASDAQ">TRIB</a>) recently provided an update on its continued development of its glucose biosensor technology. Earlier this year, the company was granted a European patent for a novel method that enhances the performance of its glucose biosensor. Recent testing of this patented process has confirmed its effectiveness in improving the performance of the sensor.
Trinity Biotech intends to use this breakthrough process to stabilize and improve the functionality of its glucose biosensor in its next-generation continuous glucose monitor (CGM) technology.
Shares of TRIB went down marginally by 0.05% in pre-market trading today following the news. However, as the company is gaining a high level of synergies from its continued development within the CGM market, this latest development might prove fruitful in strengthening its foothold in this space. Accordingly, we expect market sentiment to recover shortly.
<h2>Significance of Trinity Biotech&#39;s Patented Process</h2>
CGMs are small patch-like wearable medical devices that use biosensor wires under the skin to measure glucose in real time. Generally, these devices experience a &quot;run-in&quot; or &quot;settling&quot; period immediately after their insertion. During the run-in period, glucose readings are unreliable.&nbsp;
Trinity Biotech&#39;s patent describes a unique process within the company&#39;s reusable transmitter unit that &quot;conditions&quot; the CGM biosensor wire. This conditioning process significantly reduces this run-in time, enabling reliable measurements more quickly.&nbsp;
Additionally, the conditioning process has demonstrated notable improvements in the accuracy of the CGM device compared to laboratory reference methods for blood glucose testing. The process also improves the biosensor&#39;s mean absolute relative difference, which is the standard measure of accuracy used to compare CGM devices.
<h2>More on the News</h2>
The technology covered by this patent represents a major advancement for the company&#39;s CGM platform. The CGM technology, which Trinity Biotech acquired in January, has a unique self-inserted biosensor wire. It poses strong advantages in terms of affordability and sustainability.
The patented conditioning process will likely play an important role in further enhancing the CGM technology toward a more user-friendly and self-calibrating device.&nbsp;Along with other refinements to the biosensor, its wire design will be further evaluated in the upcoming pre-pivotal trials to create an optimized CGM that can be rapidly introduced into global markets.
<h2>Industry Prospects Favor Trinity Biotech</h2>
Per a Coherent Market Insights report, the global CGM device market was valued at $5.89 billion in 2022 and is expected to reach $12.51 billion by 2030, at a CAGR of 9.9% during the period.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/d3/77157.jpg?v=1373072611" />
Image Source: Zacks Investment Research
The market&#39;s growth is fueled by rising diabetes awareness and the increasing prevalence of diabetes among the population. The worrisome rise in the number of overweight and obese people around the world is expected to boost demand for CGM devices.&nbsp;
<h2>Recent Development by Trinity Biotech</h2>
In May, Trinity Biotech made a strategic collaboration with PulseAI to enhance the former&#39;s recently acquired CGM biosensor technology. Under the collaboration, PulseAI has access to Trinity Biotech&#39;s unique multi-parameter CGM database. Further, the data is used to design and implement Trinity Biotech&#39;s AI-driven health &amp; wellness analytics platform. This platform is a key component in Trinity Biotech&#39;s CGM solution.&nbsp;
<h2>Price Performance of Trinity Biotech</h2>
Year to date, shares of TRIB have lost 17.4% against the industry&#39;s 8.5% growth.
<h2>TRIB&#39;s Zacks Rank and Other Key Picks</h2>
TRIB currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are Intuitive Surgical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), TransMedics Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) and Boston Scientific (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>). While Intuitive Surgical and TransMedics sport a Zacks Rank #1 (Strong Buy) each, Boston Scientific currently carries a Zacks Rank #2.
Intuitive Surgical&#39;s shares have surged 58.6% in the past year. Estimates for the company&#39;s earnings have remained constant at $6.67 per share for 2024 in the past 30 days.
ISRG&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.
Estimates for TransMedics&#39; 2024 earnings per share have moved up 48.1% to $1.20 in the past 30 days. Shares of the company have risen 134% in the past year compared with the industry&#39;s 12.8% growth.
TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.
Estimates for Boston Scientific&#39;s 2024 EPS have increased 1.7% to $2.40 in the past 30 days. In the past year, shares of BSX have risen 51.5% compared with the industry&#39;s 15.5% growth.
In the last reported quarter, BSX delivered an earnings surprise of 6.90%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.18%.
<a href="https://www.zacks.com/stock/news/2334051/will-trinity-biotech-stock-gain-from-its-latest-patent-process?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2334051">To read this article on Zacks.com click here.</a>

Trinity Biotech plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today provided an update on the continued development of its glucose biosensor technology.&nbsp; Earlier this year Trinity Biotech was granted a European patent (EP3703565) for a novel method that enhances the performance of an indwelling sensor, such as a glucose biosensor. Recent testing of this patented process has confirmed its effectiveness in improving the performance of Trinity Biotech's glucose biosensor. Trinity Biotech intends to use this breakthrough process to stabilise and improve the functionality of the glucose biosensor in its next generation continuous glucose monitor (CGM) technology.&nbsp; &nbsp;
CGMs are small patch-like wearable medical devices that use biosensor wires under the skin to measure glucose in real-time. These devices are increasingly popular in diabetes management and health monitoring. &nbsp;

Trinity Biotech Provides An Update On The Continued Development Of Its Continuous Glucose Monitor Technology; Says Recent Testing Of This Patented Process Has Confirmed Its Effectiveness In Improving The Performance Of Trinity Biotech's Glucose Biosensor

Tuesday, Trinity Biotech plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock is trading higher with a session volume of 14.32 million versus the average volume of 118.9K as per data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
The company received substantial additional orders <a href="https://www.benzinga.com/quote/trib" target="_blank" rel="noreferrer noopener">for TrinScreen HIV</a>. Due to this demand and the scaling of production capacity, the company is now increasing its expected 2024 sales revenue for TrinScreen HIV to approximately $10 million, <a href="https://www.benzinga.com/pressreleases/24/08/g40562230/trinity-biotech-announces-increased-orders-for-trinscreen-hiv-and-raises-guidance-for-2024-sales" target="_blank" rel="noreferrer noopener">up from $8 million</a>.
President and Chief Executive Officer of Trinity Biotech, John Gillard, said, &#8220;We are pleased to have scaled up our manufacturing capacity to meet the increased demand for TrinScreen HIV. &nbsp;Also, as a company with a strong presence in infectious disease, we have also increased our manufacturing capacity for our FDA 510(k) cleared viral transport medium, FlexTrans, in anticipation of potential increased customer demand due to the recently declared World Health Organization Public Health Emergency of International Concern for Mpox.&#8221;
Trinity Biotech reported second-quarter sales of $15.8 million. Strong demand and output in TrinScreen HIV drove a 14.0% year-on-year revenue increase and a 7.7% quarter-on-quarter <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/g40363015/trinity-biotech-announces-q2-2024-financial-results" rel="noreferrer noopener">revenue increase</a>.
Sales of TrinScreen HIV were $3.1 million in the second quarter.
The company reiterated guidance of approximately $20 million of annualized run-rate EBITDASO on annualized run-rate revenues of approximately $75 million by the second quarter of 2025.
This outlook is predicated solely on growth from the existing businesses, including hemoglobin testing and HIV, and planned improvements to operating margins, with no contribution from the recently acquired biosensor business.
&#8220;We do expect TrinScreen HIV gross margins to improve as 2024 progresses due to increased operational efficiency and the expected transfer of assembly to a lower-cost manufacturing location by the end of 2024,&#8221; the company said in the second-quarter earnings release.
Price Action: At last check Tuesday, TRIB stock was up 54.20% at $3.12 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40560227/johnson-johnson-aims-new-policy-for-hospital-payments-under-340b-drug-discount-program-related-to" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson Aims New Policy For Hospital Payments Under 340B Drug Discount Program Related To Its Flagship Blood Thinner And Arthritis Drugs</a>.</li>
</ul>
Don&#8217;t miss the opportunity to dominate in a volatile market at the&nbsp;<a target="_blank" href="https://www.benzinga.com/events/small-cap/global-small-cap-conference-2024/" rel="noreferrer noopener">Benzinga SmallCAP Conference</a>&nbsp;on Oct. 9-10 at the Chicago Marriott Downtown Magnificent Mile. Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you&#8217;re a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders. Secure your spot and get your tickets today!

TRIB: 105% &#x7C; <a href="https://www.benzinga.com//node/40571314">Trinity Biotech shares are trading higher after the company announced an increase in projected revenue for its TrinScreen HIV to $10 million from $8 million.</a>
&nbsp;
ADXN: 62% &#x7C; <a href="https://www.benzinga.com//node/40573063">Addex Therapeutics shares are trading higher after the company and Indivior selected clinical candidates from their GABAB positive allosteric modulator research collaboration. The company is eligible for up to $330 million on achievement of milestones and royalties.</a>
&nbsp;
TCOM 10% &#x7C; <a href="https://www.benzinga.com//node/40571241">Trip.com Group shares are trading higher following Q2 financial results.</a>

Market-Moving News for August 27th

WIIM

Trinity Biotech shares are trading higher after the company announced an increase in projected revenue for its TrinScreen HIV to $10 million from $8 million.

Shares of Trip.com Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>) rose sharply in today's pre-market trading after r<a href="https://www.benzinga.com/quote/TCOM/earnings">eporting second-quarter results.</a>
Trip.com Group posted adjusted earnings per ADS of $1.00, beating market estimates of 74 cents per share.
Trip.com Group shares jumped 9.7% to $46.45 in the pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Trinity Biotech plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) gained 87.5% to $3.75 in pre-market trading after the company announced an increase in projected revenue for its TrinScreen HIV to $10 million from $8 million.</li>
<li>Smart for Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMFL#NASDAQ">SMFL</a>) rose 50.9% to $1.63 in today's pre-market trading after the company issued an update on prospective acquisitions.</li>
<li>Society Pass Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPA#NASDAQ">SOPA</a>) gained 35.6% to $1.41 in pre-market trading after gaining 10% on Monday.</li>
<li>Tantech Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TANH#NASDAQ">TANH</a>) gained 31% to $0.2022 in pre-market trading after gaining 11% on Monday.</li>
<li>Addex Therapeutics Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) gained 16.7% to $8.74 in pre-market trading. Addex Therapeutics and Indivior announced the selection of clinical candidates from their GABAB positive allosteric modulator (PAM) research collaboration.</li>
<li>ZW Data Action Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNET#NASDAQ">CNET</a>) gained 13.5% to $0.7488 in pre-market trading after climbing over 11% on Monday.</li>
<li>Signing Day Sports, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGN#NYSE">SGN</a>) gained 12.8% to $0.3232 in pre-market trading after surging 32% on Monday.</li>
<li>Galapagos NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPG#NASDAQ">GLPG</a>) gained 7.9% to $30.62 in the pre-market trading session. Galapagos shares gained 10% on Monday after Ecor1 Capital reported a 9.9% stake in the company.</li>
<li>Tuya Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TUYA#NYSE">TUYA</a>) gained 7.4% to $1.90 in pre-market trading following second-quarter results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Nxu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXU#NASDAQ">NXU</a>) declined 12% to $0.3030 in pre-market trading.</li>
<li>QT Imaging Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTI#NASDAQ">QTI</a>) shares declined 11.2% to $0.57 in pre-market trading after falling around 5% on Monday.</li>
<li>Cheetah Net Supply Chain Service Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) shares fell 10% to $0.2961 in pre-market trading after gaining around 25% on Monday.</li>
<li>VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>) fell 9.9% to $2.18 in today's pre-market trading.</li>
<li>Addentax Group Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXG#NASDAQ">ATXG</a>) fell 8.8% to $0.56 in pre-market trading.</li>
<li>TuanChe Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TC#NASDAQ">TC</a>) fell 8.3% to $1.65 in pre-market trading after gaining 9% on Monday.</li>
<li>Intelligent Living Application Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) shares fell 8% to $0.86 in pre-market trading.</li>
<li>WM Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAPS#NASDAQ">MAPS</a>) shares declined 7.9% to $1.06 in pre-market trading after gaining 5% on Monday.</li>
<li>Gaotu Techedu Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOTU#NYSE">GOTU</a>) shares fell 7.4% to $3.78 in pre-market trading following weak quarterly earnings.</li>
<li>Ballard Power Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDP#NASDAQ">BLDP</a>) shares dipped 3.2% to $1.84 in pre-market trading after declining around 5% on Monday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40568543/dow-closes-at-record-high-while-nasdaq-tumbles-as-nvidia-falls-ahead-of-earnings-fear-greed-index-r">Dow Closes At Record High While Nasdaq Tumbles As Nvidia Falls Ahead Of Earnings: Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></li>
</ul>

Trinity Biotech Increases 2024 Sales Revenue Projection For TrinScreen HIV To $10M Vs $8M Prior Amid Strong Demand; Expands Manufacturing Capacity For HIV Tests And FlexTrans Viral Transport Medium In Response To WHO Mpox Emergency

Trinity Biotech plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>), a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, obtained an extension to demonstrate compliance with a continued listing requirement of The Nasdaq Global Select Market.

Trinity Biotech Obtains Extension To Demonstrate Compliance With Nasdaq Listing Requirements

-Second Quarter 2024 revenues are expected to fall between $15.5-$16.0 million, reflecting double digit percentage year over year growth- &nbsp;
-Reiterating financial guidance of approximately $20 million of annualized run-rate EBITDASO1 on annualized run-rate revenues of approximately $75 million by Q2 2025-
-Entered into MedScience distribution agreement in UK effective as of August 1, 2024 which encompasses clinical chemistry, infectious disease, and autoimmune products-
DUBLIN, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces preliminary second quarter 2024 revenues which are expected to fall in the $15.5-$16.0 million range, demonstrating significant growth, versus $13.9 million in total revenues reported for the second quarter of 2023. Gross margin percentage is expected to be broadly in line with that reported for the second quarter of 2023. Additionally, Trinity also announces entry into a distribution agreement in the United Kingdom (UK) with MedScience, an established distributor that is a subsidiary of the privately held Pharmed Group, a leading healthcare services provider across UK and Ireland. The distribution agreement encompasses Trinity Biotech's clinical chemistry, infectious disease, and autoimmune products in the UK and is effective as of August 1, 2024.

Trinity Biotech Preliminary Q2 2024 Revenue $15.5M-$16M; Entered Into MedScience Distribution Agreement In UK Effective As Of August 1, 2024 Which Encompasses Clinical Chemistry, Infectious Disease, And Autoimmune Product

<a href="https://sam.gov/opp/05464da507eb41a69c3ccf9b5030d592/view" title="https://sam.gov/opp/05464da507eb41a69c3ccf9b5030d592/view">https://sam.gov/opp/05464da507eb41a69c3ccf9b5030d592/view</a>

Department Of Veterans Affairs Awards $4M Contract To Trinity Biotech Subsidiary, Biopool US, Inc. For Analytical Laboratory Instrument Manufacturing, Cost-Per-Test Services (66 III)

Trinity Biotech shares are trading lower after the company entered into an ATM offering agreement with Craig-Hallum Capital Group.

On July 12, 2024, Trinity Biotech plc (the "Company") entered into an At the Market Offering Agreement (the "Sales Agreement") with Craig-Hallum Capital Group LLC ("Craig-Hallum"), pursuant to which the Company may sell up to $5,500,000 of its American Depositary Shares ("ADSs"), each ADS representing 20 of the Company's A Ordinary Shares, par value $0.0109 per share, from time to time, through Craig-Hallum, acting as sales agent.
Subject to the terms and conditions of the Sales Agreement, the Company will, from time to time, set the parameters for the sale of ADSs, including any price, time or size limits or other customary parameters or conditions, and Craig-Hallum will use its commercially reasonable efforts to sell the ADSs when requested by the Company. The Sales Agreement is filed herewith as Exhibit 1.1.
In the Sales Agreement, the Company has agreed to provide Craig-Hallum with customary indemnification rights.&nbsp; The Company will also pay Craig-Hallum a commission equal to 3.0% of the gross sales price of ADSs sold pursuant to the Sales Agreement.
Sales of the ADSs under the Sales Agreement may be made by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended.

Offerings

On July 12, 2024, Trinity Biotech Entered Into An ATM Offering Agreement With Craig-Hallum Capital Group, Pursuant To Which May Sell Up To $5.5M Of Its ADSs, Each ADS Representing 20 Of The Company's A Ordinary Shares (Co Will Also Pay Craig-Hallum A Commission Equal To 3% Of The Gross Sales Price Of ADSs)

Trinity Biotech shares are trading higher after the company appointed Louise Tallon as CFO.

Trinity Biotech plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the appointment of Louise Tallon as Chief Financial Officer ("CFO"). Louise will join Trinity Biotech in August 2024. Des Fitzgerald, who has acted as interim CFO since December 2023 will continue as interim CFO until late July 2024. &nbsp;
Commenting on the appointment, John Gillard, CEO of Trinity Biotech plc, said "We are delighted to welcome Louise, who brings extensive experience in transformation and growth within a dynamic environment. This skill set, combined with her extensive experience in the life sciences product commercialisation industry, will elevate the continued development of the organisation as we continue to deliver on our corporate strategy of delivering our comprehensive transformation plan and introducing our next generation continuous glucose monitor, or CGM, to global markets. With the CFO transition we also reiterate our financial guidance and intend to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized revenues of approximately $75 million by Q2 2025."

Management

Trinity Biotech Announces Appointment Of Louise Tallon As Chief Financial Officer; Des Fitzgerald Will Continue As Interim CFO Until Late July 2024;  Reiterates Financial Guidance And Intend To Achieve ~$20M Of Annualized Run-Rate EBITDASO On Annualized Revenues Of ~$75M By Q2 2025

Trinity Biotech Has Received Regulatory Approval To Conduct Initial European Pre-Pivotal Trial, The Data Will Be Utilized To Advance The Technical Optimization Of The Next Generation CGM Device Ahead Of The Pivotal Trial Planned In 2025

<h3>Gainers</h3>
<ul>
<li>Elutia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELUT#NASDAQ">ELUT</a>) stock rose 24.2% to $4.31 during Tuesday's regular session. The market value of their outstanding shares is at $104.9 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock rose 20.61% to $2.75. The company's market cap stands at $26.0 million. </li>
<li>Akari Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKTX#NASDAQ">AKTX</a>) shares moved upwards by 20.26% to $3.03. The company's market cap stands at $35.5 million. </li>
<li>Kronos Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRON#NASDAQ">KRON</a>) shares increased by 16.71% to $1.11. The market value of their outstanding shares is at $66.7 million. </li>
<li>Black Diamond Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) shares increased by 15.72% to $5.91. The market value of their outstanding shares is at $332.7 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares moved upwards by 14.85% to $0.53. The market value of their outstanding shares is at $32.8 million. As per the news, the Q1 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) stock decreased by 25.2% to $2.26 during Tuesday's regular session. The company's market cap stands at $144.3 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock decreased by 14.8% to $1.44. The company's market cap stands at $20.3 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock declined by 14.07% to $1.65. The company's market cap stands at $1.6 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock decreased by 10.8% to $0.5. The market value of their outstanding shares is at $2.5 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) stock fell 10.74% to $0.23. The company's market cap stands at $3.9 million. </li>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) shares declined by 10.42% to $2.88. The market value of their outstanding shares is at $46.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEMD

AKTX

BDTX

BSGM

CCLD

ELUT

KRON

PROK

STRM

TOVX

12 Health Care Stocks Moving In Tuesday's Intraday Session

Trinity Biotech Q1 EPADS $(0.37) Up From $(0.76) YoY, Sales $14.70M Down From $14.83M YoY

Trinity Biotech Announces Strategic Collaboration With PulseAI To Enhance Continuous Glucose Monitor Biosensor Technology

Trinity Biotech plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received substantial additional orders for TrinScreen HIV, bringing total orders received to date for supply in 2024 to approximately $6 million. &nbsp;
The Company has successfully scaled up production to meet the increased demand for its rapid HIV tests.
As a result of this strong momentum in demand and the successful scaling of production capacity, the Company has increased its expected 2024 sales revenue for TrinScreen HIV to over $8 million.

Contracts

Trinity Biotech Receives Increased Orders For TrinScreen HIV, Total Orders Received To Date For Supply In 2024 To ~$6M; Increased Its Expected 2024 Sales Revenue For TrinScreen HIV To Over $8M

Trinity Biotech (TRIB) has released an update. Trinity Biotech plc has strategically bolstered its marketing leadership by appointing David Ouston ...

Trinity Biotech Strengthens Team with New Director

Trinity stock soars post-market on raised guidance, increased capacity

Trinity Biotech (TRIB) has released an update. Trinity Biotech plc has announced a significant increase in orders for its TrinScreen HIV test, lead...

Trinity Biotech Raises 2024 Revenue Forecast

Trinity Biotech (TRIB) has released an update. Trinity Biotech plc has announced the filing of a prospectus supplement which pertains to the offeri...

Trinity Biotech Files Prospectus Supplement for ADS Offering

Voxx International Corp., Trinity Biotech Plc, and Ensysce Biosciences are the 3 Penny Stocks to watch on August 29, based on&nbsp;TipRanks' Penny ...

3 Penny Stocks to Watch Now, 8/29/24

Trinity Biotech (TRIB) has released an update. Trinity Biotech plc has appointed Adrian Donohue as its new Chief Commercial Officer, a move that si...

Trinity Biotech Welcomes New Chief Commercial Officer

Trinity Biotech (TRIB) has released an update. Trinity Biotech plc has released its Annual Report for 2023, detailing management estimates and rese...

Trinity Biotech Releases 2023 Annual Report

Trinity Biotech (TRIB) has released an update. Trinity Biotech plc is set to hold its Annual General Meeting on September 30, 2024, where sharehold...

Trinity Biotech Announces Upcoming AGM

Trinity Biotech (TRIB) has released an update. Trinity Biotech plc has announced significant progress in the development of their next-generation c...

Trinity Biotech Advances CGM Technology

Trinity Biotech (TRIB) has released an update. Trinity Biotech plc is advancing its presence in the diabetes management sector by initiating a mark...

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Trinity Biotech

Trinity Biotech (TRIB) Forecast

Trinity Biotech (NASDAQ:TRIB) Stock, Quote.Headers.trade-ideas